CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

Ruth M. Urbantat; Valentin Popper; Elisabeth Menschel; Michael Pfeilstöcker; Ernst Forjan; Alexander Nader; Catherine R. Sieghart; Felix Keil; Elisabeth Koller

Journal ArticleOPEN ACCESS

CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

Clinical Case Reports (2021) 9(4) 1933-1936

DOI: 10.1002/ccr3.3909

2Citations

7Readers

Abstract

CPX-351, a promising new agent for patients with treatment-related and secondary acute myeloid leukemia can lead to a severe whole-body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Author supplied keywords

References Powered by Scopus

View more at Scopus

Cited by Powered by Scopus

View more at Scopus

Cite

CITATION STYLE

APA

Urbantat, R. M., Popper, V., Menschel, E., Pfeilstöcker, M., Forjan, E., Nader, A., … Koller, E. (2021). CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report. Clinical Case Reports, 9(4), 1933–1936. https://doi.org/10.1002/ccr3.3909

Readers over time

Readers' Seniority

Researcher 2

100%

Readers' Discipline

Medicine and Dentistry 3

60%

Chemical Engineering 1

20%

Pharmacology, Toxicology and Pharmaceut... 1

20%

CPX-351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

Abstract

Author supplied keywords

References Powered by Scopus

A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

A method for estimating the probability of adverse drug reactions

Toxicology and response criteria of the Eastern Cooperative Oncology Group

Cited by Powered by Scopus

CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML

Dermatologic complications in transplantation and cellular therapy for acute leukemia

Register to see more suggestions

Cite

Readers over time

Readers' Seniority

Readers' Discipline